Redhill Biophrma ADR (RDHL) 14.55 $RDHL
RedHill Biopharma Announces Last Patient Visit in Phase IIa Study with RHB-104 for Multiple Sclerosis
Globe Newswire - Mon Aug 01, 7:07AM CDT
- The Phase IIa proof-of-concept study evaluates the safety and potential efficacy of fixed oral dose RHB-104 as an add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (RRMS)
RDHL: 14.55 (+1.42)
RedHill Biopharma Reports 2016 Second Quarter Financial Results
GlobeNewswire - Tue Jul 26, 6:05AM CDT
-- RedHill maintains a strong and debt-free balance sheet with $47.7 million in cash at the end of the second quarter, allowing the Company to continue to diligently execute its three ongoing Phase III gastrointestinal disease programs in the U.S. as well as additional clinical programs
RDHL: 14.55 (+1.42)
RedHill Biopharma Announces Research Collaboration with NIH for Potential Ebola Treatment
Globe Newswire - Wed Jul 13, 6:00AM CDT
TEL-AVIV, Israel, July 13, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"
, a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases and cancer, today announced the signing of a research collaboration agreement with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), intended to evaluate RedHill's proprietary experimental therapy for the treatment of Ebola virus disease.
RDHL: 14.55 (+1.42)
Global Gastritis Pipeline Report 2016 - Therapeutics Review of BCWorld Pharm, Daewon Pharm, Recce Limited & RedHill Biopharma Ltd. - Research and Markets
BusinessWire - Fri Jun 24, 5:59AM CDT
Research and Markets has announced the addition of the "Gastritis - Pipeline Review, H1 2016" report to their offering.
RDHL: 14.55 (+1.42)
RedHill (RDHL) Stock Up on Positive Phase I Data on Yeliva
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:11AM CDT
RedHill (RDHL) announced positive results from a phase I study on Yeliva for the treatment of advanced solid tumors.
RDHL: 14.55 (+1.42), ANIP: 61.06 (+0.46), PFE: 37.31 (+0.42), BMY: 76.19 (+1.38)
RedHill Biopharma Announces Publication Demonstrating Potential Efficacy of RHB-104 for Crohn's Disease Associated with MAP Infection
Globe Newswire - Wed Jun 22, 7:00AM CDT
- The peer-reviewed article, authored by scientists from the University of Central Florida, concludes that the triple combination of the RHB-104 active components provides excellent synergistic activity in the inhibition of mycobacterial growth, potentially leading to a new and effective treatment for Crohn's disease associated with Mycobacterium avium subspecies paratuberculosis (MAP) infection
RDHL: 14.55 (+1.42)
RedHill Biopharma Announces Positive Final Results with Primary and Secondary Endpoints Met in Phase 1 Study with YELIVA(TM) in Advanced Solid Tumors
Globe Newswire - Tue Jun 21, 8:31AM CDT
- Final results from the Phase I study with YELIVA(TM) (ABC294640) in patients with advanced solid tumors confirmed that the study, conducted at the Medical University of South Carolina (MUSC), successfully met its primary and secondary endpoints, demonstrating that the drug is well tolerated and can be safely administered to cancer patients at doses that provide circulating drug levels that are predicted to have therapeutic activity
RDHL: 14.55 (+1.42)
RedHill Biopharma Announces First Patients Dosed in Phase II Study with BEKINDA(TM) for IBS-D
GlobeNewswire - Mon Jun 20, 7:00AM CDT
-- The first patients have been dosed in the randomized, double-blind, placebo-controlled Phase II study with BEKINDA 12 mg for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) in 120 subjects in 12 clinical sites in the U.S.
RDHL: 14.55 (+1.42)
RedHill Biopharma to Present at JMP Securities Life Sciences Conference
GlobeNewswire - Wed Jun 15, 7:00AM CDT
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company", a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases and cancer, today announced that Mr. Dror Ben-Asher, RedHill's Chief Executive Officer, will present a corporate overview at the JMP Securities Life Sciences Conference, on Tuesday, June 21, 2016, at 10:30 am EDT, in New York, NY.
RDHL: 14.55 (+1.42)
RedHill Biopharma to Present at the 2016 BIO International Convention
GlobeNewswire - Tue May 31, 7:00AM CDT
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company", a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases and cancer, today announced that Mr. Adi Frish, RedHill's Senior VP Business Development & Licensing, will present a corporate overview at the 2016 BIO International Convention, on Tuesday, June 7, 2016, at 11:45 am PDT, at the Moscone Center in San Francisco, CA.
RDHL: 14.55 (+1.42)
RedHill Biopharma to Present at Jefferies 2016 Healthcare Conference
GlobeNewswire - Mon May 30, 8:00AM CDT
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company", a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases and cancer, today announced that Mr. Gilead Raday, RedHill's Chief Operating Officer, will present a corporate overview at the Jefferies 2016 Healthcare Conference, on Wednesday, June 8, 2016, at 10:00 am EDT, in New York, NY.
RDHL: 14.55 (+1.42)
RedHill Biopharma Announces National Cancer Institute Grant Supporting YELIVA(TM) Phase II Hepatocellular Carcinoma Study
Globe Newswire - Wed May 04, 7:22AM CDT
- The $1.8 million U.S. National Cancer Institute (NCI) grant, awarded to the Medical University of South Carolina (MUSC), is intended to support a research program covering a variety of solid tumor cancers, including a Phase II study with YELIVA(TM) (ABC294640) for the treatment of advanced hepatocellular carcinoma, planned to be initiated in Q3/2016 at MUSC and collaborating institutions
RDHL: 14.55 (+1.42)
RedHill Biopharma to Present at BioNetwork East 2016 Partnering Summit
GlobeNewswire - Mon Apr 25, 7:01AM CDT
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company", a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that Adi Frish, RedHill's Senior VP Business Development and Licensing, will present a corporate overview at the BioNetwork East 2016 Partnering Summit, on Monday, May 2, 2016, at 9:20 am EDT, at the Reunion Resort, Orlando, FL.
RDHL: 14.55 (+1.42)
RedHill Biopharma Reports 2016 First Quarter Financial Results
GlobeNewswire - Wed Apr 20, 6:45AM CDT
-- RedHill maintains a strong and debt-free balance sheet with approximately $53 million in cash at the end of the first quarter, allowing the Company to continue to diligently execute its strategic and operational plans, including its three ongoing Phase III gastrointestinal disease programs in the U.S.
RDHL: 14.55 (+1.42)
RedHill Biopharma Announces Last Patient Visit in Phase IIa Study with RHB-104 for Multiple Sclerosis
Globe Newswire - Mon Aug 01, 7:07AM CDT
- The Phase IIa proof-of-concept study evaluates the safety and potential efficacy of fixed oral dose RHB-104 as an add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (RRMS)
RDHL: 14.55 (+1.42)
RedHill Biopharma Reports 2016 Second Quarter Financial Results
GlobeNewswire - Tue Jul 26, 6:05AM CDT
-- RedHill maintains a strong and debt-free balance sheet with $47.7 million in cash at the end of the second quarter, allowing the Company to continue to diligently execute its three ongoing Phase III gastrointestinal disease programs in the U.S. as well as additional clinical programs
RDHL: 14.55 (+1.42)
RedHill Biopharma Announces Research Collaboration with NIH for Potential Ebola Treatment
Globe Newswire - Wed Jul 13, 6:00AM CDT
TEL-AVIV, Israel, July 13, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"
, a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases and cancer, today announced the signing of a research collaboration agreement with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), intended to evaluate RedHill's proprietary experimental therapy for the treatment of Ebola virus disease. RDHL: 14.55 (+1.42)
Global Gastritis Pipeline Report 2016 - Therapeutics Review of BCWorld Pharm, Daewon Pharm, Recce Limited & RedHill Biopharma Ltd. - Research and Markets
BusinessWire - Fri Jun 24, 5:59AM CDT
Research and Markets has announced the addition of the "Gastritis - Pipeline Review, H1 2016" report to their offering.
RDHL: 14.55 (+1.42)
RedHill (RDHL) Stock Up on Positive Phase I Data on Yeliva
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:11AM CDT
RedHill (RDHL) announced positive results from a phase I study on Yeliva for the treatment of advanced solid tumors.
RDHL: 14.55 (+1.42), ANIP: 61.06 (+0.46), PFE: 37.31 (+0.42), BMY: 76.19 (+1.38)
RedHill Biopharma Announces Publication Demonstrating Potential Efficacy of RHB-104 for Crohn's Disease Associated with MAP Infection
Globe Newswire - Wed Jun 22, 7:00AM CDT
- The peer-reviewed article, authored by scientists from the University of Central Florida, concludes that the triple combination of the RHB-104 active components provides excellent synergistic activity in the inhibition of mycobacterial growth, potentially leading to a new and effective treatment for Crohn's disease associated with Mycobacterium avium subspecies paratuberculosis (MAP) infection
RDHL: 14.55 (+1.42)
RedHill Biopharma Announces Positive Final Results with Primary and Secondary Endpoints Met in Phase 1 Study with YELIVA(TM) in Advanced Solid Tumors
Globe Newswire - Tue Jun 21, 8:31AM CDT
- Final results from the Phase I study with YELIVA(TM) (ABC294640) in patients with advanced solid tumors confirmed that the study, conducted at the Medical University of South Carolina (MUSC), successfully met its primary and secondary endpoints, demonstrating that the drug is well tolerated and can be safely administered to cancer patients at doses that provide circulating drug levels that are predicted to have therapeutic activity
RDHL: 14.55 (+1.42)
RedHill Biopharma Announces First Patients Dosed in Phase II Study with BEKINDA(TM) for IBS-D
GlobeNewswire - Mon Jun 20, 7:00AM CDT
-- The first patients have been dosed in the randomized, double-blind, placebo-controlled Phase II study with BEKINDA 12 mg for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) in 120 subjects in 12 clinical sites in the U.S.
RDHL: 14.55 (+1.42)
RedHill Biopharma to Present at JMP Securities Life Sciences Conference
GlobeNewswire - Wed Jun 15, 7:00AM CDT
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"
, a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases and cancer, today announced that Mr. Dror Ben-Asher, RedHill's Chief Executive Officer, will present a corporate overview at the JMP Securities Life Sciences Conference, on Tuesday, June 21, 2016, at 10:30 am EDT, in New York, NY. RDHL: 14.55 (+1.42)
RedHill Biopharma to Present at the 2016 BIO International Convention
GlobeNewswire - Tue May 31, 7:00AM CDT
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"
, a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases and cancer, today announced that Mr. Adi Frish, RedHill's Senior VP Business Development & Licensing, will present a corporate overview at the 2016 BIO International Convention, on Tuesday, June 7, 2016, at 11:45 am PDT, at the Moscone Center in San Francisco, CA. RDHL: 14.55 (+1.42)
RedHill Biopharma to Present at Jefferies 2016 Healthcare Conference
GlobeNewswire - Mon May 30, 8:00AM CDT
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"
, a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases and cancer, today announced that Mr. Gilead Raday, RedHill's Chief Operating Officer, will present a corporate overview at the Jefferies 2016 Healthcare Conference, on Wednesday, June 8, 2016, at 10:00 am EDT, in New York, NY. RDHL: 14.55 (+1.42)
RedHill Biopharma Announces National Cancer Institute Grant Supporting YELIVA(TM) Phase II Hepatocellular Carcinoma Study
Globe Newswire - Wed May 04, 7:22AM CDT
- The $1.8 million U.S. National Cancer Institute (NCI) grant, awarded to the Medical University of South Carolina (MUSC), is intended to support a research program covering a variety of solid tumor cancers, including a Phase II study with YELIVA(TM) (ABC294640) for the treatment of advanced hepatocellular carcinoma, planned to be initiated in Q3/2016 at MUSC and collaborating institutions
RDHL: 14.55 (+1.42)
RedHill Biopharma to Present at BioNetwork East 2016 Partnering Summit
GlobeNewswire - Mon Apr 25, 7:01AM CDT
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"
, a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that Adi Frish, RedHill's Senior VP Business Development and Licensing, will present a corporate overview at the BioNetwork East 2016 Partnering Summit, on Monday, May 2, 2016, at 9:20 am EDT, at the Reunion Resort, Orlando, FL. RDHL: 14.55 (+1.42)
RedHill Biopharma Reports 2016 First Quarter Financial Results
GlobeNewswire - Wed Apr 20, 6:45AM CDT
-- RedHill maintains a strong and debt-free balance sheet with approximately $53 million in cash at the end of the first quarter, allowing the Company to continue to diligently execute its strategic and operational plans, including its three ongoing Phase III gastrointestinal disease programs in the U.S.
RDHL: 14.55 (+1.42)
